Hospitals in the Netherlands are increasingly concerned about the availability of various types of agents that form the basis ...

When using ECOG performance status, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect ECOG performance ...

Durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin is indicated for 'the first-line treatment of adults with extensive-stage small cell lung cancer'.

starting on day −3 (BuCy); etoposide 1800 mg/m 2 i.v. on day −7, cyclophosphamide 50 mg/kg/day i.v., days −6, −5, and −4, and total body irradiation in 5 or 6 fractions (200 cGy ea ...

Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...